Dr. Dagmar Hess
Oberärztin mbF
Medizinische Onkologie und Hämatologie · Dept. I
Phase I study and pharmacokinetic of CHS-828, a guanidino-containing compound, administered orally as a single dose every 3 weeks in solid tumours: an ECSG/EORTC study
Ravaud A, Cerny T, Terret C, Wanders J, Bui B, Hess D, Droz J, Fumoleau P, Twelves C. Phase I study and pharmacokinetic of CHS-828, a guanidino-containing compound, administered orally as a single dose every 3 weeks in solid tumours: an ECSG/EORTC study. European journal of cancer (Oxford, England : 1990) 2005; 41:702-7.
01.03.2005Phase I study and pharmacokinetic of CHS-828, a guanidino-containing compound, administered orally as a single dose every 3 weeks in solid tumours: an ECSG/EORTC study
01.03.2005European journal of cancer (Oxford, England : 1990) 2005; 41:702-7
Ravaud Alain, Cerny Thomas, Terret Catherine, Wanders Jantien, Bui Binh Nguyen, Hess Dagmar, Droz Jean-Pierre, Fumoleau Pierre, Twelves Chris
Capecitabine and vinorelbine in elderly patients (> or =65 years) with metastatic breast cancer: a phase I trial (SAKK 25/99)
Hess D, Goldhirsch A, Castiglione-Gertsch M, Rufener B, Ballabeni P, Rauch D, Aebi S, Pagani O, Thürlimann B, Swiss Group of Clinical Cancer Research (SAKK). Capecitabine and vinorelbine in elderly patients (> or =65 years) with metastatic breast cancer: a phase I trial (SAKK 25/99). Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2004; 15:1760-5.
01.12.2004Capecitabine and vinorelbine in elderly patients (> or =65 years) with metastatic breast cancer: a phase I trial (SAKK 25/99)
01.12.2004Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2004; 15:1760-5
Hess Dagmar, Goldhirsch A, Castiglione-Gertsch M, Rufener B, Ballabeni P, Rauch D, Aebi S, Pagani O, Thürlimann Beat, Swiss Group of Clinical Cancer Research (SAKK)
Anastrozole ('Arimidex') versus tamoxifen as first-line therapy in postmenopausal women with advanced breast cancer: results of the double-blind cross-over SAKK trial 21/95--a sub-study of the TARGET (Tamoxifen or 'Arimidex' Randomized Group Efficacy and Tolerability) trial
Thürlimann B, Rochlitz C, Aebi S, Perey L, Pagani O, Ballabeni P, Senn I, Köberle D, Hess D, Goldhirsch A. Anastrozole ('Arimidex') versus tamoxifen as first-line therapy in postmenopausal women with advanced breast cancer: results of the double-blind cross-over SAKK trial 21/95--a sub-study of the TARGET (Tamoxifen or 'Arimidex' Randomized Group Efficacy and Tolerability) trial. Breast Cancer Res Treat 2004; 85:247-54.
01.06.2004Anastrozole ('Arimidex') versus tamoxifen as first-line therapy in postmenopausal women with advanced breast cancer: results of the double-blind cross-over SAKK trial 21/95--a sub-study of the TARGET (Tamoxifen or 'Arimidex' Randomized Group Efficacy and Tolerability) trial
01.06.2004Breast Cancer Res Treat 2004; 85:247-54
Thürlimann Beat, Rochlitz Christoph, Aebi Stefan, Perey Lucien, Pagani Olivia, Ballabeni Pierluigi, Senn Isabella, Köberle Dieter, Hess Dagmar, Goldhirsch Aron
High incidence of central nervous system involvement in patients with metastatic or locally advanced breast cancer treated with epirubicin and docetaxel
Crivellari D, Goldhirsch A, Sessa C, Graffeo R, Martinelli G, Bauer J, Borner M, Hess D, Thürlimann B, Nolé F, Lombardi D, Veronesi A, Pagani O, International Breast Cancer Study Group. High incidence of central nervous system involvement in patients with metastatic or locally advanced breast cancer treated with epirubicin and docetaxel. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2001; 12:353-6.
01.03.2001High incidence of central nervous system involvement in patients with metastatic or locally advanced breast cancer treated with epirubicin and docetaxel
01.03.2001Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2001; 12:353-6
Crivellari D, Goldhirsch A, Sessa C, Graffeo R, Martinelli G, Bauer J, Borner M, Hess Dagmar, Thürlimann Beat, Nolé F, Lombardi D, Veronesi A, Pagani O, International Breast Cancer Study Group
Epidoxorubicin and docetaxel as first-line chemotherapy in patients with advanced breast cancer: a multicentric phase I-II study
Pagani O, D'Incalci M, Zucchetti M, Graffeo R, Martinelli G, Bauer J, Borner M, Hess D, Thürlimann B, Lombardi D, Crivellari D, Nolé F, Sessa C, Goldhirsch A. Epidoxorubicin and docetaxel as first-line chemotherapy in patients with advanced breast cancer: a multicentric phase I-II study. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2000; 11:985-91.
01.08.2000Epidoxorubicin and docetaxel as first-line chemotherapy in patients with advanced breast cancer: a multicentric phase I-II study
01.08.2000Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2000; 11:985-91
Pagani O, D'Incalci M, Zucchetti M, Graffeo R, Martinelli G, Bauer J, Borner M, Hess Dagmar, Thürlimann Beat, Lombardi D, Crivellari D, Nolé F, Sessa C, Goldhirsch A
Dose-finding study of epidoxorubicin and docetaxel as first-line chemotherapy in patients with advanced breast cancer
Pagani O, Riva A, Graffeo R, Zimatore M, Zampino G, Bauer J, Borner M, Hess D, Thürlimann B, Buonadonna A, Crivellari D, Martinelli G, Sessa C, Goldhirsch A. Dose-finding study of epidoxorubicin and docetaxel as first-line chemotherapy in patients with advanced breast cancer. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1999; 10:539-45.
01.05.1999Dose-finding study of epidoxorubicin and docetaxel as first-line chemotherapy in patients with advanced breast cancer
01.05.1999Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1999; 10:539-45
Pagani O, Riva A, Graffeo R, Zimatore M, Zampino G, Bauer J, Borner M, Hess Dagmar, Thürlimann Beat, Buonadonna A, Crivellari D, Martinelli G, Sessa C, Goldhirsch A